07:00 , Oct 27, 2016 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Structural analyses Chimeric rat-human NMDA receptors could help guide the development of selective NMDA receptor PAMs for neurological diseases. The chimeric receptors were constructed by replacing the transmembrane or ligand-binding domains of various NMDA...
07:00 , Aug 25, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: NMDA receptor NR1 subtype (GRIN1; NR1)

Autoimmune disease INDICATION: Multiple sclerosis (MS) In vitro and mouse studies suggest antagonizing GRIN1 could help treat MS. In an in vitro assay of inflammation-associated blood-brain barrier (BBB) permeability, an anti-GRIN1 mAb decreased monocyte migration...
08:00 , Jan 20, 2014 |  BioCentury  |  Emerging Company Profile

Zocere: Stepping up in stroke

Zocere Inc. may have found a new way to decrease ischemic brain injury in patients following stroke. The company is developing an injectable, degradation-resistant version of the neuroprotective STEP protein that could improve patient outcomes...
07:00 , Oct 3, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Epilepsy NMDA receptor NR1 subtype (GRIN1; NR1); GRIN2B (NR2B); GABAA receptor a1 (GABRA1); GABAA receptor b3 (GABRB3) Human genome sequencing studies suggest modulating GABAA receptors...
07:00 , Sep 5, 2013 |  BC Innovations  |  Targets & Mechanisms

Epilepsy narrows down

A spate of human genetic studies has shed light on the root causes of idiopathic focal epilepsy, a common childhood form of the disease. The studies suggest that a group of epilepsies and encephalopathies marked...
07:00 , Mar 15, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Cognitive dysfunction AMPA 1 glutamate receptor (GRIA1; GLUR1); NMDA receptor NR1 subtype (GRIN1; NR1); proteasome Rat studies suggest blocking glutamate receptor degradation could help prevent...
07:00 , Mar 28, 2011 |  BC Week In Review  |  Clinical News

Prana preclinical data

In a transgenic mouse model of AD, daily 30 mg/kg oral PBT2 for 11 days significantly increased hippocampal dendritic spine density in both young and old mice vs. controls (p<0.001 for both). PBT2 also significantly...
08:00 , Dec 3, 2009 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Mouse model of schizophrenia Mice deficient in NMDA receptor subunit NR1 (Grin1; Nr1) could serve as a model of human schizophrenia. Knockout of Nr1 in...
07:00 , Oct 1, 2009 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Mouse model of schizophrenia Mice with a mutation that impairs phosphorylation of the NMDA receptor NR1 subtype (GRIN1; NR1) could help guide the development of...
08:00 , Feb 28, 2000 |  BC Week In Review  |  Company News

University of Auckland School of Medicine other research news

Auckland researchers and colleagues published in Science that administration of an oral AAV vaccine to rats generated autoantibodies against the NR1 subunit of the NMDA receptor that provided protection from epilepsy or neurological damage from...